We are making the world where everyone can live a healthy and happy life

2021
- 07Granted a license for the management of human cells etc.
- 05Approval of IND application for Phase 3 clinical trial of Furestem-AD inj by MFDS
- 04Entered into MOU with Seoul National University Bundang Hospital
- 02Acquisition of cosmetics business
2020
- 12Obtained a manufacturing license from MFDS for advanced biopharmaceuticals
- 04Signed MOU for gene and cell therapy research with G+FLAS Life Sciences
2019
- 03Signed exclusive rights for domestic sales of Furestem-AD and technology transfer agreement with HYUNDAI Bioland
2018
- 02Received IND approval for Phase 1/2a clinical trial of Furestem-RA from MFDS
2017
- 09Signed Joint Development Agreement with Germany’s Heraeus Medical GmbH for osteoarthritis stem cell therapy
2016
- 10Nominated for Korea-China Science Technology Collaboration Project – Researching stem cell therapy for neurological disorders targeted for Asians
- 10Nominated by The Ministry of Trade, Industry and Energy as a "K-BrainPower" company
- 02Signed stem cell conditioned media joint business contract with Dongwha Pharmaceutical (MOU)
2015
- 12Listed on KOSDAQ
- 08Concluded the contract of iNSC technology joint business with Orig3n of the U.S
- 08Expanded the Construction of Stem Cell GMP Center
- 08Selected for the business in the development of high tech medical technology – Phases 1/2a clinical research for Crohn’ disease
- 07Acquired ISO certificates (ISO 9001, ISO 14001)
- 06Selected for the future industry leading technology development business – R&D for cell culture system
- 01Concluded the joint business contract for the stem cell conditioned medium cosmetics with COSON.
2014
- 12Approved of Furestem-CD^® Phase 1 (added psoriasis indicant)
- 12Concluded a contract for the stem cell therapy sales right and joint development with Daewoong Pharmaceutical Inc
- 09Selected for the high tech medical technology development business – Occlusive arteriopathy preclinical
- 06Certified for Technology INNO-BIZ
- 05Approved of Furestem-RA^® Phase 1
2013
- 12Changed business name to Kangstem Biotech
- 10Selected for the parts material business – GvHD preclinical
- 06Approved of Furestem-CD^® Phases 1 & 2a
- 01Approved of Furestem-AD^® Phases 1 & 2a
2012
- 12Selected for the public health medical research development business - Psoriasis preclinical
- 05Selected for the public health medical study development business - Crohn’s disease preclinical
- 02Completed the construction of Stem Cell GMP Center
2011
- 12Selected for the industry & academy cooperative technology transfer business – Atopic Dermatitis preclinical
- 08Recognized for the company auxiliary research center by KOITA (Korea Industry & Technology Association)
- 02Certified for the venture company by KIBO (Korea Technology Finance Corporation)
2010
- 10Established Kangstem Holdings

CtyoSuppor - Model CS-25AT - Cell Box

Advantages